Aspivix is developing carevix, a device intended to replace the Pozzi forceps for stabilising the cervix during gynaecological procedures. The Vaud-based medtech raised EUR 837,800 (around CHF 790,000) from 108 investors on Capital Cell as part of its Series B2 round, to expand the clinical use of carevix.
- Announced on
- Round
- Series B
- Amount
- EUR 837,800
- Location
- Epalinges, canton of Vaud
- Sector
- Health & medtech
Investors
- Capital Cell
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic